Es gab 50 kürzliche Insider-Transaktionen für Aerovate Therapeutics, Inc. (AVTE), darunter 17 Käufe und 33 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $15.08M und die gesamten Insider-Verkäufe auf $3.92M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Dake Benjamin T, Ra Capital Management, L.p., Eldridge George A. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — AVTE
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2024-08-01 |
Dake Benjamin T |
See Remarks |
Optionsausübung (Verkauf) |
1,507 |
$1.74 |
$2.62K |
- |
| 2024-07-31 |
Dake Benjamin T |
See Remarks |
Optionsausübung (Verkauf) |
10,548 |
$1.74 |
$18.35K |
1,507 |
| 2024-06-17 |
Ra Capital Management, L.p. |
10 Percent Owner |
Informierter Kauf |
928,110 |
$1.67 |
$1.55M |
7,893,678 |
| 2024-06-14 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
15,000 |
$25.03 |
$375.45K |
5,022 |
| 2024-06-14 |
Verwijs Marinus |
Chief Technical Officer |
Informierter Verkauf |
10,600 |
$25.00 |
$265K |
- |
| 2024-06-13 |
Gillies Hunter |
Chief Medical Officer |
Informierter Verkauf |
6,000 |
$24.50 |
$147K |
5,602 |
| 2024-06-05 |
Santel Donald J |
Director |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-06-05 |
Ra Capital Management, L.p. |
10 Percent Owner |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-06-05 |
Iwicki Mark T |
Director |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-06-05 |
Dorval Allison |
Director |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-06-05 |
Dable Habib J |
Director |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-06-05 |
Resnick Joshua |
Director |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-06-05 |
Katabi Maha |
10 Percent Owner |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-06-05 |
Grayzel David S. |
Director |
RSU-Zuteilung |
12,500 |
$18.90 |
$236.25K |
12,500 |
| 2024-05-17 |
Gillies Hunter |
Chief Medical Officer |
Informierter Verkauf |
86 |
$21.86 |
$1.88K |
5,602 |
| 2024-05-16 |
Noyes Timothy P |
Chief Executive Officer |
Informierter Verkauf |
1,293 |
$21.92 |
$28.35K |
- |
| 2024-05-02 |
Verwijs Marinus |
Chief Technical Officer |
Informierter Verkauf |
1,981 |
$21.02 |
$41.63K |
- |
| 2024-05-01 |
Noyes Timothy P |
Chief Executive Officer |
Informierter Verkauf |
965 |
$20.87 |
$20.14K |
- |
| 2024-04-17 |
Gillies Hunter |
Chief Medical Officer |
Optionsausübung (Verkauf) |
3,497 |
$1.74 |
$6.08K |
539 |
| 2024-04-17 |
Dake Benjamin T |
See Remarks |
Informierter Verkauf |
68 |
$23.97 |
$1.63K |
1,291 |
| 2024-04-16 |
Noyes Timothy P |
Chief Executive Officer |
Informierter Verkauf |
5,509 |
$24.94 |
$137.41K |
- |
| 2024-04-10 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
771 |
$27.56 |
$21.25K |
1,960 |
| 2024-04-09 |
Grayzel David S. |
Director |
Informierter Verkauf |
11,882 |
$28.15 |
$334.48K |
14,502 |
| 2024-04-01 |
Noyes Timothy P |
Chief Executive Officer |
Informierter Verkauf |
1,000 |
$31.95 |
$31.95K |
- |
| 2024-04-01 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
12,495 |
$31.23 |
$390.21K |
1,960 |
| 2024-04-01 |
Dake Benjamin T |
See Remarks |
Informierter Verkauf |
3,325 |
$31.97 |
$106.32K |
1,291 |
| 2024-04-01 |
Verwijs Marinus |
Chief Technical Officer |
Informierter Verkauf |
1,504 |
$30.00 |
$45.12K |
- |
| 2024-03-28 |
Gillies Hunter |
Chief Medical Officer |
Informierter Verkauf |
9,000 |
$29.50 |
$265.5K |
3,251 |
| 2024-03-27 |
Dake Benjamin T |
See Remarks |
Informierter Verkauf |
11,068 |
$27.97 |
$309.52K |
1,291 |
| 2024-03-25 |
Dake Benjamin T |
See Remarks |
Informierter Verkauf |
3,432 |
$28.01 |
$96.12K |
1,291 |
| 2024-03-19 |
Verwijs Marinus |
Chief Technical Officer |
Informierter Verkauf |
2,764 |
$26.46 |
$73.12K |
- |
| 2024-03-18 |
Gillies Hunter |
Chief Medical Officer |
Informierter Verkauf |
613 |
$26.40 |
$16.18K |
3,251 |
| 2024-03-18 |
Dake Benjamin T |
See Remarks |
Informierter Verkauf |
7,581 |
$26.48 |
$200.76K |
1,291 |
| 2024-03-13 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
2,016 |
$25.02 |
$50.44K |
1,960 |
| 2024-03-12 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
2,051 |
$25.05 |
$51.37K |
1,960 |
| 2024-03-11 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
10 |
$26.31 |
$263.05 |
1,960 |
| 2024-03-08 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
114 |
$25.00 |
$2.85K |
1,960 |
| 2024-03-07 |
Eldridge George A |
See Remarks |
Informierter Verkauf |
22,386 |
$25.00 |
$559.69K |
1,960 |
| 2024-03-07 |
Gillies Hunter |
Chief Medical Officer |
Informierter Verkauf |
8,975 |
$24.50 |
$219.89K |
3,251 |
| 2024-03-04 |
Dable Habib J |
Director |
RSU-Zuteilung |
1,531 |
$22.49 |
$34.43K |
1,531 |
| 2024-02-23 |
Gillies Hunter |
Chief Medical Officer |
Optionsausübung (Verkauf) |
511 |
$1.74 |
$889.14 |
3,014 |
| 2024-02-20 |
Gillies Hunter |
Chief Medical Officer |
Informierter Verkauf |
898 |
$20.58 |
$18.48K |
3,251 |
| 2024-02-05 |
Niven Ralph |
Chief Scientific Officer |
Informierter Verkauf |
4,600 |
$17.45 |
$80.25K |
1,609 |
| 2024-01-29 |
Noyes Timothy P |
Chief Executive Officer |
RSU-Zuteilung |
200,000 |
$18.10 |
$3.62M |
200,000 |
| 2024-01-22 |
Niven Ralph |
Chief Scientific Officer |
RSU-Zuteilung |
66,586 |
$20.00 |
$1.33M |
66,586 |
| 2024-01-22 |
Eldridge George A |
See Remarks |
RSU-Zuteilung |
66,586 |
$20.00 |
$1.33M |
66,586 |
| 2024-01-22 |
Gillies Hunter |
Chief Medical Officer |
RSU-Zuteilung |
66,586 |
$20.00 |
$1.33M |
66,586 |
| 2024-01-22 |
Dake Benjamin T |
See Remarks |
RSU-Zuteilung |
66,586 |
$20.00 |
$1.33M |
66,586 |
| 2024-01-22 |
Verwijs Marinus |
Chief Technology Officer |
RSU-Zuteilung |
66,586 |
$20.00 |
$1.33M |
66,586 |
| 2024-01-22 |
Pigot Timothy |
Chief Commercial Officer |
RSU-Zuteilung |
66,586 |
$20.00 |
$1.33M |
66,586 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
